Toll Free: 1-888-928-9744

Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Pipeline Review, H1 2016

Published: Jun 22, 2016 | Pages: 158 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Pipeline Review, H1 2016', provides in depth analysis on Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) targeted pipeline therapeutics. 

The report provides comprehensive information on the Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274)
- The report reviews Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) Overview 8 Therapeutics Development 9 Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Products under Development by Stage of Development 9 Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Products under Development by Therapy Area 10 Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Products under Development by Indication 11 Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Pipeline Products Glance 14 Late Stage Products 14 Early Stage Products 15 Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Products under Development by Companies 16 Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Products under Development by Universities/Institutes 25 Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Therapeutics Assessment 27 Assessment by Monotherapy/Combination Products 27 Assessment by Mechanism of Action 28 Assessment by Route of Administration 29 Assessment by Molecule Type 31 Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Companies Involved in Therapeutics Development 33 Abeome Corporation 33 Alnylam Pharmaceuticals, Inc. 34 AlphaMab Co., Ltd 35 AstraZeneca Plc 36 Aurigene Discovery Technologies Limited 37 BeiGene, Ltd. 38 Bristol-Myers Squibb Company 39 CytomX Therapeutics, Inc. 40 Eli Lilly and Company 41 F. Hoffmann-La Roche Ltd. 42 Genosco 43 ImmunoCellular Therapeutics, Ltd. 44 Immunocore Limited 45 IO Biotech ApS 46 Kadmon Corporation, LLC 47 MedImmune, LLC 48 Merck KGaA 50 Novartis AG 51 PsiOxus Therapeutics Limited 52 Regeneron Pharmaceuticals, Inc. 53 Shanghai Henlius Biotech Co., Ltd. 54 Sorrento Therapeutics, Inc. 55 Sutro Biopharma, Inc. 56 Theravectys SA 57 Tikcro Technologies, Ltd. 58 ViiV Healthcare Limited 59 Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Drug Profiles 60 ALN-PDL - Drug Profile 60 Antibody to Inhibit PD-L1 for Oncology - Drug Profile 61 atezolizumab - Drug Profile 62 AUPM-327 - Drug Profile 73 avelumab - Drug Profile 74 Biologic to Inhibit PD-L1 for Immunology - Drug Profile 79 BMS-936559 - Drug Profile 80 CA-170 - Drug Profile 83 CBA-0710 - Drug Profile 85 CX-072 - Drug Profile 86 dabrafenib mesylate + durvalumab + trametinib dimethyl sulfoxide - Drug Profile 87 durvalumab - Drug Profile 88 durvalumab + gefitinib - Drug Profile 97 durvalumab + IMCgp-100 + tremelimumab - Drug Profile 98 durvalumab + MEDI-0680 - Drug Profile 99 durvalumab + MEDI-6383 - Drug Profile 100 durvalumab + MEDI-9447 - Drug Profile 101 durvalumab + monalizumab - Drug Profile 102 durvalumab + tremelimumab - Drug Profile 103 GNS-1480 - Drug Profile 106 HLX-10 - Drug Profile 107 HLX-20 - Drug Profile 108 IO-103 - Drug Profile 109 KD-033 - Drug Profile 110 KN-035 - Drug Profile 111 LY-3300054 - Drug Profile 112 Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies and Bacterial Infections - Drug Profile 113 Monoclonal Antibodies to Inhibit PD-L1 for Oncology - Drug Profile 114 Monoclonal Antibodies to Inhibit PDL1 for Oncology - Drug Profile 115 Monoclonal Antibodies to Inhibit PDL1 for Oncology - Drug Profile 116 Monoclonal Antibody to Inhibit PD-L1 for Hematological Malignancies and Solid Tumors - Drug Profile 117 Monoclonal Antibody to Inhibit PD-L1 for Oncology - Drug Profile 118 Monoclonal Antibody to Inhibit PD-L1 for Oncology - Drug Profile 119 Monoclonal Antibody to Inhibit PD-L1 for Oncology - Drug Profile 120 Monoclonal Antibody to Inhibit PDL-1 for Influenza - Drug Profile 121 Monoclonal Antibody to Target EGFR and Inhibit PD-L1 for Oncology - Drug Profile 122 MSB-002 - Drug Profile 123 Oncolytic Viruses to Inhibit PDL1 for Solid Tumors - Drug Profile 124 Small Molecules to Inhibit PD-L1 and PD-L2 for Oncology - Drug Profile 125 STIA-1011 - Drug Profile 126 STIA-1012 - Drug Profile 127 STIA-1014 - Drug Profile 128 STIA-1015 - Drug Profile 129 Synthetic Peptide 1 to Inhibit PD-L1 for Oncology - Drug Profile 130 Synthetic Peptide 2 to Inhibit PDL1 for Oncology - Drug Profile 131 Vaccine to Target CD274 and CD279 for Bladder Cancer - Drug Profile 132 Vaccine to Target CD274 and CD279 for Colorectal Cancer - Drug Profile 133 Vaccine to Target CD274 and CD279 for Renal Cell Carcinoma - Drug Profile 134 Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Dormant Projects 135 Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Discontinued Products 136 Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Featured News & Press Releases 137 Appendix 153 Methodology 153 Coverage 153 Secondary Research 153 Primary Research 153 Expert Panel Validation 153 Contact Us 153 Disclaimer 154
List of Tables
Number of Products under Development for, H1 2016 13 Number of Products under Development by Therapy Area, H1 2016 14 Number of Products under Development by Indication, H1 2016 15 Comparative Analysis by Late Stage Development, H1 2016 18 Comparative Analysis by Early Stage Products, H1 2016 19 Number of Products under Development by Companies, H1 2016 20 Products under Development by Companies, H1 2016 21 Products under Development by Companies, H1 2016 (Contd..1) 22 Products under Development by Companies, H1 2016 (Contd..2) 23 Products under Development by Companies, H1 2016 (Contd..3) 24 Products under Development by Companies, H1 2016 (Contd..4) 25 Products under Development by Companies, H1 2016 (Contd..5) 26 Products under Development by Companies, H1 2016 (Contd..6) 27 Products under Development by Companies, H1 2016 (Contd..7) 28 Number of Products under Investigation by Universities/Institutes, H1 2016 29 Products under Investigation by Universities/Institutes, H1 2016 30 Assessment by Monotherapy/Combination Products, H1 2016 31 Number of Products by Stage and Mechanism of Action, H1 2016 32 Number of Products by Stage and Route of Administration, H1 2016 34 Number of Products by Stage and Molecule Type, H1 2016 36 Pipeline by Abeome Corporation, H1 2016 37 Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016 38 Pipeline by AlphaMab Co., Ltd, H1 2016 39 Pipeline by AstraZeneca Plc, H1 2016 40 Pipeline by Aurigene Discovery Technologies Limited, H1 2016 41 Pipeline by BeiGene, Ltd., H1 2016 42 Pipeline by Bristol-Myers Squibb Company, H1 2016 43 Pipeline by CytomX Therapeutics, Inc., H1 2016 44 Pipeline by Eli Lilly and Company, H1 2016 45 Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 46 Pipeline by Genosco, H1 2016 47 Pipeline by ImmunoCellular Therapeutics, Ltd., H1 2016 48 Pipeline by Immunocore Limited, H1 2016 49 Pipeline by IO Biotech ApS, H1 2016 50 Pipeline by Kadmon Corporation, LLC, H1 2016 51 Pipeline by MedImmune, LLC, H1 2016 52 Pipeline by Merck KGaA, H1 2016 54 Pipeline by Novartis AG, H1 2016 55 Pipeline by PsiOxus Therapeutics Limited, H1 2016 56 Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 57 Pipeline by Shanghai Henlius Biotech Co., Ltd., H1 2016 58 Pipeline by Sorrento Therapeutics, Inc., H1 2016 59 Pipeline by Sutro Biopharma, Inc., H1 2016 60 Pipeline by Theravectys SA, H1 2016 61 Pipeline by Tikcro Technologies, Ltd., H1 2016 62 Pipeline by ViiV Healthcare Limited, H1 2016 63 Dormant Projects, H1 2016 139 Discontinued Products, H1 2016 140


List of Figures
Number of Products under Development for, H1 2016 13 Number of Products under Development by Therapy Area, H1 2016 14 Number of Products under Development by Top 10 Indication, H1 2016 15 Comparative Analysis by Late Stage Development, H1 2016 18 Comparative Analysis by Early Stage Products, H1 2016 19 Assessment by Monotherapy/Combination Products, H1 2016 31 Number of Products by Stage and Mechanism of Actions, H1 2016 32 Number of Products by Routes of Administration, H1 2016 33 Number of Products by Stage and Routes of Administration, H1 2016 33 Number of Products by Molecule Types, H1 2016 35 Number of Products by Stage and Molecule Type, H1 2016 35

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global aquafeed market size is anticipated to be valued at USD 165.04 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in fish consumption for direct and indirect consumer applications is anticipated to drive the marke

Read More...

Global alpha olefins market size is likely to be valued at USD 10.7 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing polyethylene demand for use in plastic production is anticipated to drive market growth. Growing ap

Read More...

Global fumaric acid market size is anticipated to be valued at USD 764.8 million by 2020, as per a new research report by Radiant Insights, Inc. Growing processed food demand coupled with RTD (ready-to-drink) beverages consumption is expected to driv

Read More...

Global 3D scanning market is expected to be valued at USD 4,900.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing need for speedy and precise results with high efficiency is anticipated to drive the industry. 3D

Read More...

Global Aerial Work Platform (AWP) truck market is expected to be valued at USD 8,003.7 million by 2022, as per a new research report by Radiant Insights, Inc. Rapid infrastructure growth due to rising real estate investment is expected to drive the i

Read More...
Choose License Type
Single User - US $3500
Multi User - US $7000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify